Wholesale Acquisition Cost Information for Colorado Prescribers

In accordance with the Colorado Wholesale Acquisition Cost Disclosure Law (Colorado Revised Statutes Section 12-42.5-308), Astellas is disclosing to authorized prescribers of prescription drugs in Colorado certain required wholesale acquisition cost (WAC) pricing information for Astellas-marketed products.

Please choose a product from the list, and select "WAC Information" below.

AMBISOME® (amphotericin B)	WAC Information
ASTAGRAF XL® (tacrolimus)	WAC Information
CRESEMBA® (Isavuconazonium sulfate)	WAC Information
IZERVAY™ (avacincaptad pegol intravitreal solution)	WAC Information
LEXISCAN® (regadenoson)	WAC Information
MYRBETRIQ® (mirabegron)	WAC Information
PROGRAF® (tacrolimus) and PROGRAF® GRANULES (tacrolimus for oral suspension)	WAC Information
VESICARE® (solifenacin)	WAC Information
VYLOY® (zolbetuximab - clzb)	WAC Information

XOSPATA® (gilteritinib)	WAC Information
XTANDI® (enzalutamide)	WAC Information
PADCEV® (enfortumab vedotin-ejfv)	WAC Information
VEOZAH® (fezolinetant)	WAC Information

The pricing information disclosed represents the WAC price, which represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers. WAC does not represent actual transaction prices and does not include discounts, rebates or reductions in price. The price paid by patients to acquire the products listed is often different than the WAC prices listed, and most patients do not pay WAC. How much a patient will pay will depend on the patient's insurance coverage. To learn the exact cost of a prescription, patients should contact their health insurance company or preferred pharmacy. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.

The listing of generic products in the disclosure forms does not imply that such products are interchangeable with the Astellas-marketed product or have the same efficacy or safety. Please refer to each product's U.S. Food and Drug Administration (FDA)-approved prescribing information for further information. To access approved prescribing information for Astellas-marketed products in the US, visit here.

The prescribing information approved by the FDA must continue to guide appropriate use of Astellas medicines. The intent of this website is only to provide wholesale acquisition price information to authorized prescribers of prescription drugs in Colorado in accordance with Colorado law. For more detailed information or healthcare advice, members of the public should consult their healthcare professionals.